Free tool
FAERS Monitor: Lisraya
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220106 or its brand name (Lisraya, Brepocitinib Tosylate). Reports on generic versions are filed under their own applications.
Reports
8
Serious
6
75% of reports
Hospitalization
4
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- herpes zoster2
- acute respiratory failure1
- blood creatine phosphokinase increased1
- drug ineffective1
- dyspnoea1
- hot flush1
- interstitial lung disease1
- malaise1
- maternal exposure during pregnancy1
- pyrexia1
- rash1
- rhinovirus infection1
- skin bacterial infection1
- tachycardia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin bacterial infection | 1 | 3277.4 | 523.3 | 817 |
| rhinovirus infection | 1 | 675.7 | 108.0 | 168 |
| acute respiratory failure | 1 | 136.7 | 21.8 | 33 |
| herpes zoster | 2 | 91.5 | 27.6 | 100 |
| blood creatine phosphokinase increased | 1 | 91.3 | 14.6 | 22 |
| interstitial lung disease | 1 | 54.3 | 8.7 | 13 |
| hot flush | 1 | 34.9 | 5.6 | 8 |
| tachycardia | 1 | 29.6 | 4.7 | 6 |
| maternal exposure during pregnancy | 1 | 29.5 | 4.7 | 6 |
| pyrexia | 1 | 7.6 | 1.2 | 1 |
| rash | 1 | 6.0 | 1.0 | 1 |
| malaise | 1 | 6.0 | 1.0 | 1 |
| dyspnoea | 1 | 4.6 | 0.7 | 0 |
| drug ineffective | 1 | 2.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.